Forager Capital Management, a major shareholder of Quipt Home Medical, has provided missing context from Quipt’s recent public statements. Forager aims to ensure Quipt completes a transaction at the highest possible price and prevent the Board from avoiding a sale. They criticize the Board’s strategy to discredit Forager and stall a sale. Forager reduced its offer from $3.90 to $3.10 due to declining free cash flow and the Board’s self-serving equity grants. They urge Quipt to engage seriously in a potential transaction and deliver value to shareholders.

Forager’s offer of $3.10 per share represents a 120% premium to the unaffected trading price and reflects a 19x multiple of FCF – a premium compared to public peers and precedent transactions. Forager accuses the Board of avoiding constructive engagement and suing Forager when they attempted to engage in a potential transaction. Shareholders are urged to question the Board’s motives and demand a fair outcome.

Read more at Yahoo Finance: Forager says Quipt board ‘motivated by self-serving tactics’